Ocuphire Pharma Investor Day Presentation Deck
DR
DME
29
Key Eligibility Criteria in ZETA-1
Given Bilateral Treatment with Oral, Patient Criteria Allows DME in Fellow Eye
INCLUSION
●
●
EXCLUSION
Retinopathy from causes other than diabetes in study eye
Presence of center involved diabetic macular edema (DME) defined as a central
subfield thickness (CST) ≥ 320 µm on SD-OCT or the presence of intra- or subretinal
fluid within the central subfield
●
●
●
●
Moderately-severe to severe NPDR or mild PDR in study eye as confirmed by reading
center
BCVA > 20/63 in study eye
●
Center involved DME in the fellow eye is allowed
Prior treatment in study eye with focal/grid laser photocoagulation within the past year, PRP
at any time, systemic or intravitreal anti-VEGF agents within last 6 months in study eye
HbA1c ≥ 12.0%
Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis,
cancer, hepatic, renal, endocrine, or cardiovascular disorders) that might interfere as
deemed by Investigator
ZETA-1 Clinical Trial
Ocuphire
PHARMAView entire presentation